Haemophilia Trial, Recruiting NCT06684314 Sponsor: Sanofi Condition: Haemophilia
Back to Haemophilia

Haemophilia Trial, Recruiting

NCT06684314
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with moderate or severe hemophilia A, meaning your body makes very little or none of a clotting protein called Factor VIII (5% or less than normal)
  • You either have never developed inhibitors (antibodies that block treatment) or have not had detectable inhibitors for at least three years
  • You have recently started treatment with a medication called efanesoctocog alfa as part of your regular care, no more than three months before joining the study
  • You are 6 years old or older and are able to have an MRI scan (sedation can be provided if needed, based on the doctor's judgment)
  • You are able to have your joints examined as part of the study
  • Your doctor decided to prescribe efanesoctocog alfa for you before and separately from this study — not because of the study
  • You (or your parent/legal guardian if you are under the legal age of consent) have signed and agreed to participate, and children will also be asked for their own agreement where local rules require it

Who may not be able to join:

  • You have a blood clotting disorder other than hemophilia A
  • You have been diagnosed with any other known bleeding disorder
  • You are currently receiving Factor VIII therapy but it does not seem to be working as well as expected
  • Your ankle joints already show significant damage based on X-ray scoring above a certain level (confirm with trial site)
  • You are currently taking part in another clinical trial or have taken an experimental medication within the last 3 months
  • You are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-633-1610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
11 November 2024
Est. completion
28 August 2031

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change from baseline in total scores of the Hemophilia Joint Health Score (HJHS) for all joints; Change from baseline in annualized joint bleeding rate (AjBR) for treated and untreated bleeds; Number of target joint development, resolution and/or recurrence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov